BioLineRx Ltd
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the t… Read more
BioLineRx Ltd (BLRX) - Net Assets
Latest net assets as of September 2025: $19.53 Million USD
Based on the latest financial reports, BioLineRx Ltd (BLRX) has net assets worth $19.53 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($39.80 Million) and total liabilities ($20.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $19.53 Million |
| % of Total Assets | 49.07% |
| Annual Growth Rate | -2.67% |
| 5-Year Change | -38.9% |
| 10-Year Change | -71.73% |
| Growth Volatility | 74.62 |
BioLineRx Ltd - Net Assets Trend (2008–2024)
This chart illustrates how BioLineRx Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioLineRx Ltd (2008–2024)
The table below shows the annual net assets of BioLineRx Ltd from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $13.46 Million | +1.80% |
| 2023-12-31 | $13.22 Million | -73.99% |
| 2022-12-31 | $50.84 Million | -25.33% |
| 2021-12-31 | $68.09 Million | +209.06% |
| 2020-12-31 | $22.03 Million | -34.00% |
| 2019-12-31 | $33.38 Million | -19.22% |
| 2018-12-31 | $41.32 Million | -21.86% |
| 2017-12-31 | $52.88 Million | +50.97% |
| 2016-12-31 | $35.03 Million | -26.43% |
| 2015-12-31 | $47.61 Million | +49.88% |
| 2014-12-31 | $31.77 Million | +171.90% |
| 2013-12-31 | $11.68 Million | -21.96% |
| 2012-12-31 | $14.97 Million | -33.56% |
| 2011-12-31 | $22.53 Million | -39.53% |
| 2010-12-31 | $37.26 Million | +19.68% |
| 2009-12-31 | $31.13 Million | +50.02% |
| 2008-12-31 | $20.75 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioLineRx Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 32998188500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $38.10 Million | 283.02% |
| Other Comprehensive Income | $16.13 Million | 119.84% |
| Other Components | $359.06 Million | 2667.41% |
| Total Equity | $13.46 Million | 100.00% |
BioLineRx Ltd Competitors by Market Cap
The table below lists competitors of BioLineRx Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Enero Group Ltd
AU:EGG
|
$15.18 Million |
|
Green Packet Bhd
KLSE:0082
|
$15.20 Million |
|
Hanryu Holdings, Inc. Common Stock
NASDAQ:HRYU
|
$15.20 Million |
|
Alpine Select AG
SW:ALPN
|
$15.20 Million |
|
Abans Holdings Limited
NSE:AHL
|
$15.18 Million |
|
Creas F&C Co.Ltd
KQ:110790
|
$15.18 Million |
|
Cagdas Cam Sanayi ve Ticaret A.S.
IS:CGCAM
|
$15.17 Million |
|
ORIGIN MATER. A DL-0001
F:5ER
|
$15.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioLineRx Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 13,223,000 to 13,461,000, a change of 238,000 (1.8%).
- Net loss of 9,221,000 reduced equity.
- New share issuances of 16,357,000 increased equity.
- Other comprehensive income decreased equity by 861,000.
- Other factors decreased equity by 6,037,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.22 Million | -68.5% |
| Share Issuances | $16.36 Million | +121.51% |
| Other Comprehensive Income | $-861.00K | -6.4% |
| Other Changes | $-6.04 Million | -44.85% |
| Total Change | $- | 1.80% |
Book Value vs Market Value Analysis
This analysis compares BioLineRx Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.08x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.00x to 16.08x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $1270.80 | $2.71 | x |
| 2009-12-31 | $1932.01 | $2.71 | x |
| 2010-12-31 | $44.88 | $2.71 | x |
| 2011-12-31 | $27.35 | $2.71 | x |
| 2012-12-31 | $13.26 | $2.71 | x |
| 2013-12-31 | $7.79 | $2.71 | x |
| 2014-12-31 | $14.69 | $2.71 | x |
| 2015-12-31 | $13.89 | $2.71 | x |
| 2016-12-31 | $9.36 | $2.71 | x |
| 2017-12-31 | $8.82 | $2.71 | x |
| 2018-12-31 | $5.71 | $2.71 | x |
| 2019-12-31 | $3.42 | $2.71 | x |
| 2020-12-31 | $1.31 | $2.71 | x |
| 2021-12-31 | $1.54 | $2.71 | x |
| 2022-12-31 | $0.99 | $2.71 | x |
| 2023-12-31 | $0.21 | $2.71 | x |
| 2024-12-31 | $0.17 | $2.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioLineRx Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -68.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -31.86%
- • Asset Turnover: 0.74x
- • Equity Multiplier: 2.89x
- Recent ROE (-68.50%) is above the historical average (-93.08%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -154.48% | 0.00% | 0.00x | 1.48x | $-34.14 Million |
| 2009 | -50.31% | -96.26% | 0.39x | 1.35x | $-18.78 Million |
| 2010 | 5.63% | 6.57% | 0.73x | 1.17x | $-1.63 Million |
| 2011 | -58.52% | -20.63% | 2.18x | 1.30x | $-15.44 Million |
| 2012 | -136.37% | -18.04% | 4.66x | 1.62x | $-21.91 Million |
| 2013 | -151.01% | -15.59% | 5.67x | 1.71x | $-18.81 Million |
| 2014 | -32.03% | 0.00% | 0.00x | 1.14x | $-13.35 Million |
| 2015 | -30.25% | 0.00% | 0.00x | 1.08x | $-19.16 Million |
| 2016 | -45.23% | 0.00% | 0.00x | 1.11x | $-19.34 Million |
| 2017 | -46.05% | 0.00% | 0.00x | 1.15x | $-29.64 Million |
| 2018 | -55.57% | 0.00% | 0.00x | 1.36x | $-27.09 Million |
| 2019 | -76.23% | 0.00% | 0.00x | 1.60x | $-28.78 Million |
| 2020 | -136.27% | 0.00% | 0.00x | 2.15x | $-32.22 Million |
| 2021 | -39.73% | 0.00% | 0.00x | 1.20x | $-33.86 Million |
| 2022 | -49.08% | 0.00% | 0.00x | 1.50x | $-30.04 Million |
| 2023 | -458.40% | -1262.79% | 0.08x | 4.83x | $-61.94 Million |
| 2024 | -68.50% | -31.86% | 0.74x | 2.89x | $-10.57 Million |
Industry Comparison
This section compares BioLineRx Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioLineRx Ltd (BLRX) | $19.53 Million | -154.48% | 1.04x | $15.18 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |